


403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.




UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of DirectorsHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox »YahooSearchSearchSign inU.S. Markets open in 8 hrs 6 minsS&P 5002,469.91-2.63 (-0.11%)Dow 3021,513.17-66.90 (-0.31%)Nasdaq6,410.81+23.05 (+0.36%)LISTENAetna's CEO Mark Bertolini on the future of the health care systemBertolini shares how a life-threatening injury shaped his views on health care.UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of DirectorsGlobeNewswire•May 16, 2017ReblogShareTweetShareRA’ANANA, Israel and NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the appointment of Fred E. Cohen, MD, DPhil, to its Board of Directors. Dr. Cohen will also serve on the Board’s Compensation, Nomination and Governance Committee.Arie Belldegrun, MD, UroGen Pharma’s Chairman, commented, “We are excited to welcome Fred to the UroGen Board of Directors.  As one of the leaders of TPG’s healthcare efforts over the past decade, Fred has played an integral part in building many successful biotech companies and brings with him a tremendous track-record of creating tangible shareholder value.  We look forward to having access to Fred’s vast industry experience and his leadership on the board.”Dr. Cohen commented, “I am excited to be joining UroGen’s Board of Directors.  UroGen is passionate about changing treatment paradigms in bladder and upper tract carcinomas with the potential to improve the lives of patients. This is a pivotal time to be joining the company.  I look forward to playing a guiding role in helping UroGen to emerge as a leader in uro-oncology.”Dr. Cohen is a Senior Advisor to TPG Capital, where he served for over 15 years as a Partner, and founder of TPG Biotechnology, a life science focused venture capital fund.  In addition, for over two decades throughout his career, Dr. Cohen has been affiliated with UCSF where he held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism.  Dr. Cohen received his BS degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, and his MD from Stanford.  Dr. Cohen currently serves on the Board of Directors of several biotechnology and pharmaceutical companies.About UroGen Pharma Ltd.UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer.Forward Looking StatementsThis press release contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen Pharma’s business strategy, clinical development plan and operating plans. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: UroGen Pharma’s anticipated growth strategies; the anticipated trends and challenges in UroGen Pharma’s business and the markets in which it operates; UroGen Pharma’s ability to attract or retain key management and personnel; the size and growth of the potential markets for UroGen Pharma’s product candidates and its ability to serve those markets; and the rate and degree of market acceptance of UroGen Pharma’s product candidates vis-à-vis alternative therapies. Moreover, UroGen Pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for UroGen Pharma’s management to predict all risks, nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements contained herein. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.Read More ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextHere's Trump's approval rating in every stateBusiness InsiderThe Navy's newest, most sophisticated aircraft carrier doesn't have urinalsBusiness InsiderObamacare is hurting these people—and Congress is doing nothing about itYahoo FinanceChina is crushing American tech titansYahoo Finance VideoMcDonald's, GM, and Domino's — What you need to know in markets on TuesdayYahoo FinanceFirst ‘Avengers: Infinity War’ Trailer LeakedInvestorPlaceUnder Armour ripped up Jordan Spieth's old contract before he won his first major and gave him a 10-year deal, and it's already paid off big timeBusiness InsiderThe $180 million conflict that kept Scaramucci out of the White House in January has only gotten shadierBusiness InsiderGoogle's forward guidance trumps earnings any day: NYSE traderYahoo Finance VideoStocks rangebound ahead of big earningsYahoo FinanceThe one question you should always ask in a job interview, according to Wharton's top professorCNBCAetna's CEO Mark Bertolini on the future of the health care systemYahoo FinanceNew analysis shows North Korea's ICBM is basically uselessBusiness InsiderSaudi Arabia is cutting oil exports out of desperation: NYSE traderYahoo Finance VideoEarnings won't matter if Q2 GDP disappoints investorsYahoo FinanceAlphabet beats revenue forecast, but warns about rising costsReutersDemocrats take aim at big companies in economic blueprintTruth: Perfect. The Dems just gave the Republicans the White House for the next eight years.Join the Conversation1 / 52.3k











403 - Forbidden: Access is denied.



Server Error


403 - Forbidden: Access is denied.
You do not have permission to view this directory or page using the credentials that you supplied.








UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors Nasdaq:URGN









































































English
Français











Register
Sign In













UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors




















May 16, 2017 08:15 ET

 | Source: UroGen Pharma






RA’ANANA, Israel and NEW YORK, May  16, 2017  (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the appointment of Fred E. Cohen, MD, DPhil, to its Board of Directors. Dr. Cohen will also serve on the Board’s Compensation, Nomination and Governance Committee. Arie Belldegrun, MD, UroGen Pharma’s Chairman, commented, “We are excited to welcome Fred to the UroGen Board of Directors.  As one of the leaders of TPG’s healthcare efforts over the past decade, Fred has played an integral part in building many successful biotech companies and brings with him a tremendous track-record of creating tangible shareholder value.  We look forward to having access to Fred’s vast industry experience and his leadership on the board.” Dr. Cohen commented, “I am excited to be joining UroGen’s Board of Directors.  UroGen is passionate about changing treatment paradigms in bladder and upper tract carcinomas with the potential to improve the lives of patients. This is a pivotal time to be joining the company.  I look forward to playing a guiding role in helping UroGen to emerge as a leader in uro-oncology.” Dr. Cohen is a Senior Advisor to TPG Capital, where he served for over 15 years as a Partner, and founder of TPG Biotechnology, a life science focused venture capital fund.  In addition, for over two decades throughout his career, Dr. Cohen has been affiliated with UCSF where he held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism.  Dr. Cohen received his BS degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, and his MD from Stanford.  Dr. Cohen currently serves on the Board of Directors of several biotechnology and pharmaceutical companies. About UroGen Pharma Ltd. UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. Forward Looking Statements This press release contains forward-looking statements. All statements contained herein other than statements of historical fact constitute forward-looking statements, including statements regarding UroGen Pharma’s business strategy, clinical development plan and operating plans. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: UroGen Pharma’s anticipated growth strategies; the anticipated trends and challenges in UroGen Pharma’s business and the markets in which it operates; UroGen Pharma’s ability to attract or retain key management and personnel; the size and growth of the potential markets for UroGen Pharma’s product candidates and its ability to serve those markets; and the rate and degree of market acceptance of UroGen Pharma’s product candidates vis-à-vis alternative therapies. Moreover, UroGen Pharma operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for UroGen Pharma’s management to predict all risks, nor can they assess the impact of all factors on its business or the extent to which any such factor or combination of factors may cause actual results to differ materially from those contained herein. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur, and UroGen Pharma’s actual results could differ materially and adversely from those anticipated or implied by the forward-looking statements contained herein. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.  CONTACT:
Gary Titus, UroGen Pharma Ltd.
689 Fifth Avenue, 14th Floor
New York, NY 10022
garyt@urogen.com 
646-768-9531

Stephanie Carrington, ICR, Inc. 
685 Third Avenue, 2nd Floor 
New York, NY 10017
stephanie.carrington@icrinc.com 
646-277-1282


Related Articles
other press releases by UroGen Pharma


Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
July 19, 2017 08:30


UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
June 02, 2017 08:00


UroGen Pharma to Present at the Jefferies 2017 Global Healthcare Conference
May 30, 2017 08:00


UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting
May 11, 2017 08:00


UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
May 10, 2017 08:00






225



other news releases in

Directors and Officers

in the last 30 days
                            











Profile

UroGen Pharma





  Subscribe via RSS
 Subscribe via ATOM
 Javascript



  New York, New York, UNITED STATES




Contact Data
CONTACT:
Gary Titus, UroGen Pharma Ltd.
689 Fifth Avenue, 14th Floor
New York, NY 10022
garyt@urogen.com 
646-768-9531

Stephanie Carrington, ICR, Inc. 
685 Third Avenue, 2nd Floor 
New York, NY 10017
stephanie.carrington@icrinc.com 
646-277-1282

Contact



With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!



Already have an account?  Log in here.











Media Files



UroGen Pharma  Logo






LOGO URL | Copy the link below
            





Formats available:






                            Original
                        




                            Medium
                        




                            Small
                        



















Newswire Distribution Network & Management



Home
Newsroom
RSS Feeds
Legal
Contact Us






About Us
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
            




Contact Us


Corporate Headquarters
2321 Rosecrans Avenue.
Suite 2200
El Segundo, CA 90245
Phone: (800) 307-6627
Fax:  (800) 307-3567
            


European Headquarters
Woolgate Exchange,
25 Basinghall Street,
London EC2V 5HA
UK
Phone: +1 866-465-8454




© 2017 GlobeNewswire, Inc. All Rights Reserved.








Insider Trading - Cohen Fred E - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Cohen Fred E





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2017-01-01Option Award
2017-01-047:47 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
3,391
$0
22,630(Direct)
View


2017-01-01Option Award
2017-01-047:17 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
340
$29.39
65,578(Direct)
View


2016-12-01Option Award
2016-12-022:03 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
1,788
$5.59
115,867(Direct)
View


2016-11-15Option Award
2016-11-168:02 pm
N/AN/A
Tandem Diabetes Care Inc
TNDM
Cohen Fred EDirector
17,000
$1.9
17,000(Direct)
View


2016-10-01Option Award
2016-10-047:46 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
2,643
$0
19,239(Direct)
View


2016-10-01Option Award
2016-10-047:43 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
345
$28.92
65,238(Direct)
View


2016-09-01Option Award
2016-09-063:24 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
2,433
$4.11
114,079(Direct)
View


2016-07-15Option Award
2016-07-197:01 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
5,000
$0
16,596(Direct)
View


2016-07-15Option Award
2016-07-197:01 pm
N/A2026-07-15
Caredx Inc.
CDNA
Cohen Fred EDirector
9,745
$4.95
16,596(Direct)
View


2016-07-01Option Award
2016-07-067:32 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
2,695
$0
11,596(Direct)
View


2016-07-01Option Award
2016-07-066:42 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
373
$26.74
64,893(Direct)
View


2016-06-22Option Award
2016-06-2409:14 am
2017-06-222026-06-21
Roka Bioscience Inc.
ROKA
Cohen Fred EDirector
30,000
$0.68
30,000(Direct)
View


2016-06-20Option Award
2016-06-208:09 pm
2017-06-202026-06-20
Veracyte Inc
VCYT
Cohen Fred EDirector
10,000
$5.28
10,000(Direct)
View


2016-06-16Option Award
2016-06-205:49 pm
N/A2026-06-16
Caredx Inc.
CDNA
Cohen Fred EDirector
5,255
$5.02
5,255(Direct)
View


2016-06-10Option Award
2016-06-145:24 pm
2017-06-102026-06-10
Genomic Health Inc
GHDX
Cohen Fred EDirector
10,000
$26.18
10,000(Direct)
View


2016-05-31Option Award
2016-06-0209:42 am
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
2,581
$3.39
111,646(Direct)
View


2016-05-23Option Award
2016-05-253:07 pm
2016-06-232026-05-23
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
30,000
$3.22
30,000(Direct)
View


2016-05-19Option Award
2016-05-232:58 pm
N/A2026-05-19
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
10,000
$42.25
0(Direct)
View


2016-04-01Option Award
2016-04-055:29 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
1,954
$0
8,901(Direct)
View


2016-04-01Option Award
2016-04-048:58 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
392
$25.48
64,520(Direct)
View


2016-02-29Option Award
2016-03-014:03 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
4,396
$1.99
109,065(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/AN/A
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$8.49
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/AN/A
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$5.54
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/AN/A
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$7.26
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/AN/A
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
12,500
$12.7
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/A2021-07-13
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$8.49
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/A2022-07-10
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$5.54
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/A2023-07-18
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
4,065
$7.26
24,807(Direct)
View


2016-01-11Exercise
2016-01-135:05 pm
N/A2024-05-15
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
12,500
$12.7
24,807(Direct)
View


2016-01-01Option Award
2016-01-058:21 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
1,836
$0
6,947(Direct)
View


2016-01-01Option Award
2016-01-054:17 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
284
$35.2
64,128(Direct)
View


2015-11-30Option Award
2015-12-034:19 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
824
$10.61
104,669(Direct)
View


2015-11-16Option Award
2015-11-175:15 pm
N/AN/A
Tandem Diabetes Care Inc
TNDM
Cohen Fred EDirector
17,000
$10.13
17,000(Direct)
View


2015-10-01Option Award
2015-10-055:06 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
1,008
$0
5,111(Direct)
View


2015-10-01Option Award
2015-10-055:01 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
468
$21.34
63,844(Direct)
View


2015-08-31Option Award
2015-09-022:22 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
751
$11.64
103,845(Direct)
View


2015-07-01Option Award
2015-07-069:12 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
1,227
$0
4,103(Direct)
View


2015-07-01Option Award
2015-07-065:03 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
365
$27.34
63,376(Direct)
View


2015-06-24Option Award
2015-06-264:06 pm
N/A2025-06-23
Roka Bioscience Inc.
ROKA
Cohen Fred EDirector
15,000
$2.75
15,000(Direct)
View


2015-06-16Option Award
2015-06-179:00 pm
N/A2025-06-16
Caredx Inc.
CDNA
Cohen Fred EDirector
5,255
$6.08
5,255(Direct)
View


2015-06-12Option Award
2015-06-165:22 pm
N/A2025-06-11
Five Prime Therapeutics Inc
FPRX
Cohen Fred EDirector
12,500
$22.15
12,500(Direct)
View


2015-06-12Option Award
2015-06-154:18 pm
2016-06-122026-06-12
Genomic Health Inc
GHDX
Cohen Fred EDirector
10,000
$26.01
10,000(Direct)
View


2015-05-29Option Award
2015-06-013:53 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
780
$11.21
103,094(Direct)
View


2015-05-20Option Award
2015-05-222:49 pm
2015-06-202025-05-20
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
15,000
$11.39
15,000(Direct)
View


2015-05-19Option Award
2015-05-216:34 pm
2016-05-192025-05-18
Veracyte Inc
VCYT
Cohen Fred EDirector
10,000
$10.41
10,000(Direct)
View


2015-04-01Option Award
2015-04-036:26 pm
N/AN/A
Caredx Inc.
CDNA
Cohen Fred EDirector
1,075
$0
2,876(Direct)
View


2015-04-01Option Award
2015-04-034:21 pm
N/AN/A
Genomic Health Inc
GHDX
Cohen Fred EDirector
328
$30.43
63,011(Direct)
View


2015-02-27Option Award
2015-03-033:45 pm
N/AN/A
Biocryst Pharmaceuticals Inc
BCRX
Cohen Fred EDirector
857
$10.2
102,314(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Tue, 25 Jul 2017 00:24:05 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  














Who We Are















































WHO WE ARE

ABOUT US
AGE OF EVIDENCE
LEADERSHIP
Executive Team
Board of Directors
Advisors
CONTACT US



WHAT WE DO

OUR APPROACH
OUR TECHNOLOGY



OUR PRODUCTS

OVERVIEW
AFIRMA&REG;
PERCEPTA&REG;
ENVISIA&TRADE;
PUBLICATIONS & ABSTRACTS



INVESTORS

OVERVIEW
PRESS RELEASES
EVENTS & PRESENTATIONS
CORPORATE GOVERNANCE
Executive Leadership
Board of Directors
Committee Composition
SEC FILINGS
STOCK INFORMATION
ANALYST COVERAGE
INVESTOR FAQS
INFORMATION REQUESTS



NEWSROOM

PRESS RELEASES
IN THE NEWS
CORPORATE RECOGNITION
MEDIA RESOURCES
SIGN UP FOR NEWS UPDATES



JOIN OUR TEAM

OUR CULTURE
JOB OPENINGS


SEARCH










WHO WE ARE

ABOUT US
AGE OF EVIDENCE
LEADERSHIP
Executive Team
Board of Directors
Advisors
CONTACT US



WHAT WE DO

OUR APPROACH
OUR TECHNOLOGY



OUR PRODUCTS

OVERVIEW
AFIRMA&REG;
PERCEPTA&REG;
ENVISIA&TRADE;
PUBLICATIONS & ABSTRACTS



INVESTORS

OVERVIEW
PRESS RELEASES
EVENTS & PRESENTATIONS
CORPORATE GOVERNANCE
Executive Leadership
Board of Directors
Committee Composition
SEC FILINGS
STOCK INFORMATION
ANALYST COVERAGE
INVESTOR FAQS
INFORMATION REQUESTS



NEWSROOM

PRESS RELEASES
IN THE NEWS
CORPORATE RECOGNITION
MEDIA RESOURCES
SIGN UP FOR NEWS UPDATES



JOIN OUR TEAM

OUR CULTURE
JOB OPENINGS
























						Who We Are					








Board of Directors





Executive Team
Board of Directors
Advisors

Fred E. Cohen, M.D., D.Phil.


    Fred E. Cohen, M.D., D.Phil., F.A.C.P., has served as a director since January 2007.  Dr. Cohen is a TPG Partner and Managing Director, having joined TPG in 2001, and serves as co-head of TPG’s biotechnology group.  Dr. Cohen is also a former member of the faculty at the University of California, San Francisco, where he taught and conducted research from 1988 through 2014.  Dr. Cohen also serves as a director of the following public companies:  Genomic Health Inc., a company focused on providing actionable genomic health information; Five Prime Therapeutics, Inc., a clinic-stage biotechnology company focused on discovering and developing novel protein therapeutics; Tandem Diabetics Care, Inc., a medical device company that designs, develops and commercializes products for people with insulin-dependent diabetes; BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development of novel, small-molecule drugs that block key enzymes involved in infectious and rare diseases; Roka BioScience, Inc., a food safety diagnostics business; and CareDx, Inc., a molecular diagnostics business focused on organ transplant recipients. He is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences.  Dr. Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biosphysics from Oxford University, where he was a Rhodes Scholar, and an M.D. from Stanford Univeristy.

























BioCryst Pharmaceuticals Inc. :: Board of Directors







































HomeAbout BioCrystCompany OverviewPartners & Business DevelopmentLeadership TeamBoard of DirectorsCorporate GovernanceCommittee CompositionCode of Business ConductCommittee ChartersCareersOpportunitiesOur SciencePipeline & ProductRAPIVABNext generation kallikrein inhibitors for HAEBCX4430InvestorsAnalyst CoverageEvents & PresentationsEmail AlertsFinancial ProfileInvestor FaqInformation RequestNewsProxy OnlineSEC DocumentsStock InformationContact IRNews & ResourcesLatest NewsHAE PublicationsBCX4430 Publications







Board of Directors 




Home | Contact Us | Site Map




GO








Print this page




Board of Directors 






Board of Directors 


George B. Abercrombie
Fred E. Cohen, M.D., D.Phil
Stanley C. Erck
Nancy Hutson, Ph.D.
Robert A. Ingram
Kenneth B. Lee, Jr.
Sanj K. Patel
Jon P. Stonehouse






Robert A. Ingram, Chairman of the Board



Robert A. Ingram was appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. Mr. Ingram joined Hatteras Venture Partners, a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine, as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome, a pharmaceutical company. He co-led the merger and integration that formed GlaxoSmithKline (GSK) in December 2000. He subsequently served as the Chief Operating Officer and President of Pharmaceutical Operations at GSK from January 2001 to January 2003. He served as Vice Chairman Pharmaceuticals of GSK, acting as a special advisor to GSK’s corporate executive team, until January 1, 2010. Mr. Ingram serves as Chairman of the Board of Novan, Inc., a pharmaceutical company, and as Lead Independent Director of Cree, Inc., a manufacturer of semiconductor light-emitting diode materials and devices. Mr. Ingram also serves as a member of the board of directors of HBM Healthcare Investments, Ltd., a publicly traded Swiss investment company, and of Malin Corporation plc, a publicly traded life sciences company based in Ireland. Mr. Ingram also serves as Chairman of Viamet Pharmaceuticals, Inc., a private company focused on anti-infective research, and a director of PhaseBio Pharmaceuticals, Inc., a private clinical-stage biopharmaceutical company. Mr. Ingram graduated from Eastern Illinois University with a B.S. degree in Business Administration. In addition to his professional responsibilities, Mr. Ingram formed and chaired the CEO Roundtable on Cancer at the request of former President George H. W. Bush, and he is a member of numerous other civic and professional organizations. Mr. Ingram is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, Research Triangle Institute, Research Triangle Foundation and Chairman, North Carolina GlaxoSmithKline Foundation. Mr. Ingram’s extensive experience in the pharmaceutical industry as both an executive and director and his private investment expertise contribute valuable insight and expertise to the Board.


Back to Top








George B. Abercrombie



George B. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. He most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible leading operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie currently holds the position of Senior Vice President and Chief Commercial Officer at Innoviva, Inc., a publicly traded bio-pharmaceutical asset management company.  He also serves on the Board of Brickell Biotech, a private pharmaceutical company. Additionally, he is an Adjunct Professor at Duke University’s Fuqua School of Business and a board member of the North Carolina GlaxoSmithKline Foundation. Mr. Abercrombie’s executive experience in the pharmaceutical industry and management positions with major pharmaceutical companies provide an excellent background for service on the Board.


Back to Top








Fred E. Cohen, M.D., D.Phil



Fred E. Cohen, M.D., D.Phil. was appointed to the Board in July 2013. In 2001, Dr. Cohen joined TPG Capital, a private investment firm, to initiate and lead TPG’s venture efforts in biotechnology and life sciences. He retired from this role at the end of 2016 and now serves as a Senior Advisor to TPG. Beginning in 1986, and until his retirement in 2016, Dr. Cohen served as a member of the faculty of University of California, San Francisco (UCSF). At UCSF, Dr. Cohen served as an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. His research interests include structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. Currently, Dr. Cohen also serves on the Board of Directors of Genomic Health, Inc., Veracyte, Inc., Tandem Diabetes Care, Inc., Five Prime Therapeutics, Inc., Roka Bioscience, Inc., UroGen Pharma Ltd. and CareDx, Inc., as well as on the Boards of several privately held companies. Dr. Cohen’s extensive expertise in the pharmaceutical industry, private investment expertise and experience serving on boards of biotechnology companies contribute valuable insight and experience to the Board. 


Back to Top








Stanley C. Erck



Stanley C. Erck was appointed to the Board in December 2008. Mr. Erck has over 30 years of executive leadership experience in the pharmaceutical industry. Mr. Erck has served as President, CEO and Director of Novavax, Inc., a publicly traded biopharmaceutical company since 2011, having previously served as Executive Chairman from 2010 to 2011, and he has served as a director of Novavax since 2009. From 2000 through 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a biopharmaceutical company, leading the company through an initial public offering and a merger with Intercell AG, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, Inc., a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics Inc. (now Genzyme Corp.), and in management positions within Baxter International Inc. In addition to Novavax, Mr. Erck currently sits on the Board of Directors of MaxCyte, Inc., a publicly traded company developing cell based medicines. He received his undergraduate degree from the University of Illinois and his MBA from the University of Chicago Graduate School of Business. Mr. Erck’s executive experience in the biotech industry and his management positions with major pharmaceutical companies, including his experience with late-stage product candidate development, provide an excellent background for service on the Board.


Back to Top








Nancy Hutson, Ph.D.



Dr. Hutson was appointed to the Board in January 2012, bringing over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc. in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as Director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Currently, Dr. Hutson currently serves on the board of directors for Cubist Pharmaceuticals, Inc. and Endo International plc., the Scientific Advisory Board of Hatteras Venture Partners and is an active member on the board of directors for Planned Parenthood of Connecticut. She is also involved in several professional societies, including but not limited to, the American Association for the Advancement of Science and the American Physiological Society. Dr. Hutson received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University.

Back to Top








Kenneth B. Lee, Jr.



Kenneth B. Lee, Jr. was appointed to the Board in June 2011. Mr. Lee has over 40 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is currently a General Partner with Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently Managing Director of the firm’s health sciences corporate finance group, and at one time served as the National Director of the Life Sciences Practice. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently on the Board of Directors of Aralez, Inc., and serves on the Board of a private company, Clinipace. Previously, Mr. Lee served on the Boards of Abgenix, CV Therapeutics, Inspire Pharmaceuticals, Maxygen, OSI Pharmaceuticals and Clinverse. He has served in various leadership capacities on these Boards, including Chairman of the Board, Independent Lead Director and Chairman of Audit and Compensation Committees. Mr. Lee’s experience advising biotechnology companies regarding financial and partnering strategies, his extensive background in finance and his experience serving on the Boards of biotech companies contribute valuable insight and experience to the Board.


Back to Top








Sanj K. Patel



Sanj K. Patel is the Chairman and CEO of Kiniksa Pharmaceuticals, which was formed in 2015 to develop therapies for patients with devastating diseases and unmet medical need. He brings more than 25 years of experience in the pharmaceutical and biotech industries and has a combination of scientific, clinical and commercial skills. Sanj K. Patel created Synageva in June 2008 to focus on rare diseases, and designed and initiated its lead program (Kanuma®) for Lysosomal Acid Lipase Deficiency (LAL Deficiency) in July 2008. Kanuma was approved globally in 2015 as the first therapy for patients suffering from LAL Deficiency. He took the company public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in less than 5 years. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.5B (including cash), which represented the highest premium ever paid for a biotech company valued over $5B.

Prior to Synageva, he was at Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics franchise and led the U.S. launch of Myozyme®, in addition to sales and marketing responsibility for Cerezyme®, Fabrazyme® and Aldurazyme®. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council for all Genzyme divisions, including Therapeutics, Oncology and Transplant. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization of several treatments. Notably, Sanj led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, Sanj held roles in clinical research and commercial operations with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa/Otsuka Pharmaceuticals. Sanj obtained his BSc with Honors in Biotechnology from the University of the South Bank, London. He completed his management and business studies at Ealing College, London and his Pharmacology research program at the Wellcome Foundation. Sanj is a member of the Board of Directors for Syros Pharmaceuticals and BioCryst Pharmaceuticals, both publicly traded biotechnology companies. He is also the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic organization that supports various charities supporting patients with rare and devastating diseases.


Back to Top








Jon P. Stonehouse



Jon P. Stonehouse joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and acquisitions, global licensing and business development, corporate strategy and alliance management. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck & Co., Inc. In 2008 and 2011, respectively, Mr. Stonehouse joined the Advisory Boards of Precision Biosciences, Inc., a private biotechnology company and Genscript, a private bioservices company.  Also in December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota. As Chief Executive Officer and President of BioCryst, Mr. Stonehouse brings to the Board an intimate knowledge of our business, and his executive experience in a variety of capacities at major pharmaceutical companies provides industry-specific operational experience that is beneficial to the Board.


Back to Top






















